Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monovalent avian influenza virus-like particle H5N1 + adjuvant 1
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Monovalent avian influenza virus-like particle H5N1 + adjuvant 1 is a recombinant vaccine candidate developed by Novavax for the prevention of H5N1 avian influenza. The vaccine utilizes virus-like particle (VLP) technology, where the viral hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins are expressed to form particles that structurally resemble the A/Indonesia/05/05 (H5N1) virus but lack genetic material, rendering them non-infectious. The formulation includes Adjuvant 1, which is Novavax's proprietary saponin-based adjuvant (Matrix-M), designed to enhance the magnitude and breadth of the immune response. Clinical development has primarily focused on evaluating the safety and immunogenicity of various dose levels of the VLP antigen in combination with the adjuvant in healthy adults.
- Other names
- H5N1 pandemic influenza virus-like particle vaccineH-5N1 pandemic influenza virus-like particle vaccineH 5N1 pandemic influenza virus-like particle vaccineA/Indonesia/05/05 (H5N1) VLP vaccineH5N1 VLP vaccine + Matrix-M
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on monovalent avian influenza virus-like particle H5N1 + adjuvant 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monovalent avian influenza virus-like particle H5N1 + adjuvant 1.